Effectiveness and cost-utility of telemonitoring lab results and e-consultations in rheumatoïd artritis.
Not yet recruiting
- Conditions
- Rheumatoïd arthritis10003816
- Registration Number
- NL-OMON52237
- Lead Sponsor
- Maasstadziekenhuis
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 142
Inclusion Criteria
- Diagnosis of rheumatoid arthritis as stated by the rheumatologist;
- Reported Patient Reported Outcomes Measures;
- Minimum age of 18 years;
- Able to provide informed consent;
- Literacy in Dutch.
Exclusion Criteria
- Arthritis other than rheumatoid arthritis;
- Unable to take blood samples via lancets.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The main study parameters are the effects measured in Patient Reported<br /><br>Outcomes, making use of the EQ-5D questionnaires and the societal costs<br /><br>associated with the implementation of telemonitoring amongst RA patients. </p><br>
- Secondary Outcome Measures
Name Time Method <p>N/A</p><br>
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie telemonitoring's impact on rheumatoid arthritis disease progression?
How does telemonitoring of lab results compare to traditional monitoring in rheumatoid arthritis treatment outcomes?
Which biomarkers are associated with response prediction to e-consultations in rheumatoid arthritis management?
What adverse events are reported in telemonitoring-based rheumatoid arthritis interventions and how are they managed?
Are there combination approaches involving telemonitoring and biologic DMARDs that improve cost-utility in rheumatoid arthritis?